KANCERA IS DEVELOPING A NEW GENERATION OF CANCER DRUGS

 

COMBATTING RECURRENCE OF TUMORS

One of the biggest problems in cancer medicine is the reappearance of tumors after apparently successful treatment. These recurring tumors are often more malignant and resistant to treatment and are a common cause of death.

Current cancer drugs are rather blunt instruments. Many pharmaceuticals are toxic and side effects are frequent, so research is moving towards a new era of targeted molecular treatments.

Kancera combines industrial and clinical experience with frontline research to target the mechanisms of tumor recurrence and develop candidate drugs for new molecular targets.

We start with new treatment concepts and end with the sale of candidate drugs for further clinical development.

Kancera was founded in the spring of 2010. On February 25, 2011, the share was listed on NASDAQ OMX First North.

ABOUT US

Kancera AB is a biotechnology company that focuses on the development and sale of drug candidates that have the potential to cure or stop the progression of cancer.

RESEARCH & DEVELOPMENT

Currently, four projects are being run aimed at developing new, effective treatments for both haematological forms of cancer (leukaemia) and solid tumours.

INVESTOR RELATIONS

Kancera’s share was linked into the NASDAQ OMX First North on February 25, 2011. Here, you will find information about the share as well as the option to download a prospectus, annual reports, and other reports.

CALENDAR
59th ASH Annual Meeting & Exposition
DEC 09

Full Year Report for Kancera AB (publ), January 1-December 31, 2017.
FEB-20